{"id":"netarsudil-ophthalmic","safety":{"commonSideEffects":[{"rate":"50-60","effect":"Conjunctival hyperemia"},{"rate":"10-15","effect":"Corneal verticillata"},{"rate":"5-10","effect":"Eye pain or discomfort"},{"rate":"5-10","effect":"Blurred vision"},{"rate":"5","effect":"Conjunctival hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL4594250","moleculeType":"Small molecule","molecularWeight":"453.54"},"_dailymed":{"setId":"b1d71f41-be06-4a08-94d4-e352198f09c2","title":"ROCKLATAN (NETARSUDIL AND LATANOPROST OPHTHALMIC SOLUTION, 0.02%/0.005%) SOLUTION/ DROPS [ALCON LABORATORIES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Netarsudil works through dual mechanisms: it inhibits Rho-associated protein kinase (ROCK), which increases trabecular meshwork outflow facility and reduces episcleral venous pressure, and it blocks the norepinephrine transporter, which decreases aqueous humor production. These combined effects result in significant intraocular pressure reduction in glaucoma and ocular hypertension patients.","oneSentence":"Netarsudil is a Rho kinase inhibitor and norepinephrine transporter antagonist that reduces intraocular pressure by increasing conventional outflow and decreasing episcleral venous pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:59.658Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07325240","phase":"PHASE4","title":"24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-11-21","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":30},{"nctId":"NCT06819046","phase":"","title":"Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment","status":"COMPLETED","sponsor":"Colorado Ophthalmology Associates PC","startDate":"2025-02-14","conditions":"Glaucoma","enrollment":70},{"nctId":"NCT07465913","phase":"PHASE4","title":"Rocklatan vs Latanoprost Post-DSLT","status":"NOT_YET_RECRUITING","sponsor":"Eye Centers of Southeast Texas","startDate":"2026-05-06","conditions":"Glaucoma","enrollment":36},{"nctId":"NCT07082816","phase":"PHASE3","title":"Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alcon Research","startDate":"2025-09-02","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":489},{"nctId":"NCT06394973","phase":"PHASE2","title":"Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2024-08-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":161},{"nctId":"NCT07074782","phase":"","title":"Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues","status":"NOT_YET_RECRUITING","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2026-01","conditions":"Glaucoma","enrollment":1500},{"nctId":"NCT06441643","phase":"PHASE2","title":"Next Generation Rocklatan","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-09-04","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":426},{"nctId":"NCT07209410","phase":"PHASE4","title":"Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma","status":"RECRUITING","sponsor":"Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,","startDate":"2025-11-01","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT06033703","phase":"PHASE1, PHASE2","title":"Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2025-01-14","conditions":"Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy","enrollment":48},{"nctId":"NCT07048886","phase":"PHASE4","title":"Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)","status":"NOT_YET_RECRUITING","sponsor":"Center for Sight Las Vegas","startDate":"2025-07-15","conditions":"Primary Open Angle Glaucoma","enrollment":68},{"nctId":"NCT06865144","phase":"PHASE4","title":"Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT","status":"RECRUITING","sponsor":"East Coast Institute for Research","startDate":"2025-06-27","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":70},{"nctId":"NCT06960629","phase":"","title":"The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital Dubrava","startDate":"2025-04-01","conditions":"Pseudophakic Bullous Keratopathy, Glaucoma","enrollment":50},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT06969586","phase":"","title":"The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital Dubrava","startDate":"2025-04-01","conditions":"Fuchs Endothelial Corneal Dystrophy, Cataract, Glaucoma","enrollment":50},{"nctId":"NCT05660447","phase":"PHASE2, PHASE3","title":"A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wills Eye","startDate":"2023-02-06","conditions":"Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy","enrollment":80},{"nctId":"NCT05283395","phase":"PHASE4","title":"Rocklatan® Evaluation","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2022-03-28","conditions":"Glaucoma","enrollment":136},{"nctId":"NCT04752020","phase":"EARLY_PHASE1","title":"Netarsudil Use After Descemtorhexis Without Endothelial Keratoplasty","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2021-03-28","conditions":"Fuchs' Endothelial Dystrophy","enrollment":25},{"nctId":"NCT01997879","phase":"PHASE1","title":"Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2013-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT04620135","phase":"PHASE3","title":"Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2020-11-30","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":245},{"nctId":"NCT03971357","phase":"PHASE2, PHASE3","title":"Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration","status":"TERMINATED","sponsor":"Price Vision Group","startDate":"2019-07-22","conditions":"Fuchs' Endothelial Dystrophy","enrollment":19},{"nctId":"NCT04498169","phase":"PHASE2","title":"A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2020-09-17","conditions":"Corneal Edema","enrollment":40},{"nctId":"NCT04064918","phase":"NA","title":"Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity","status":"WITHDRAWN","sponsor":"University of California, San Diego","startDate":"2021-12","conditions":"OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension","enrollment":""},{"nctId":"NCT04401982","phase":"","title":"Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2021-03-15","conditions":"Ocular Hypertension, Suspect Glaucoma","enrollment":10},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT04051463","phase":"PHASE2, PHASE3","title":"Rhopressa for Corneal Edema Associated With Fuchs Dystrophy","status":"COMPLETED","sponsor":"Price Vision Group","startDate":"2019-08-05","conditions":"Fuchs Endothelial Dystrophy","enrollment":29},{"nctId":"NCT04981886","phase":"PHASE4","title":"Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma","status":"UNKNOWN","sponsor":"Salus University","startDate":"2021-08","conditions":"Normal Tension Glaucoma","enrollment":115},{"nctId":"NCT03248037","phase":"PHASE3","title":"Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation","status":"COMPLETED","sponsor":"Cornea Research Foundation of America","startDate":"2017-09-05","conditions":"Fuchs' Endothelial Dystrophy, Bullous Keratopathy","enrollment":120},{"nctId":"NCT04057053","phase":"EARLY_PHASE1","title":"Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2018-10-02","conditions":"Fuchs' Endothelial Dystrophy, Cataract","enrollment":10},{"nctId":"NCT03844945","phase":"PHASE2","title":"Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2019-03-19","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":215},{"nctId":"NCT03808688","phase":"PHASE4","title":"Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2018-12-27","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":261},{"nctId":"NCT04234932","phase":"EARLY_PHASE1","title":"Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation","status":"UNKNOWN","sponsor":"University of the Incarnate Word","startDate":"2020-01-06","conditions":"Glaucoma, Open-Angle","enrollment":10},{"nctId":"NCT03310580","phase":"PHASE2","title":"Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-11-15","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":42},{"nctId":"NCT03233308","phase":"PHASE2","title":"Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-10-20","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":20},{"nctId":"NCT02558400","phase":"PHASE3","title":"Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2015-09-18","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":718},{"nctId":"NCT02057575","phase":"PHASE2","title":"Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2014-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":298},{"nctId":"NCT02674854","phase":"PHASE3","title":"Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2016-02","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":750},{"nctId":"NCT01528787","phase":"PHASE2","title":"Study of AR-13324 in Patients With Elevated Intraocular Pressure","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2012-03","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":85},{"nctId":"NCT02874846","phase":"PHASE2","title":"Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2016-07","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":12},{"nctId":"NCT01731002","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2012-11","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":224},{"nctId":"NCT02207491","phase":"PHASE3","title":"Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2014-07","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":411},{"nctId":"NCT02558374","phase":"PHASE3","title":"Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2015-09","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":708},{"nctId":"NCT02246764","phase":"PHASE3","title":"Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2014-09","conditions":"Ocular Hypertension, Glaucoma","enrollment":93},{"nctId":"NCT02207621","phase":"PHASE3","title":"Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2014-07","conditions":"Ocular Hypertension, Open-angle Glaucoma","enrollment":756},{"nctId":"NCT02406287","phase":"PHASE1","title":"A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2015-04","conditions":"Healthy Subjects","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Latanoprost Ophthalmic","Rhopressa","Rhopressa®"],"phase":"marketed","status":"active","brandName":"Netarsudil Ophthalmic","genericName":"Netarsudil Ophthalmic","companyName":"University of the Incarnate Word","companyId":"university-of-the-incarnate-word","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Netarsudil ophthalmic solution is a small molecule used to treat conditions such as open-angle glaucoma, ocular hypertension, glaucoma, Fuchs' endothelial dystrophy, and cataract. It is administered as a 0.02% solution, and its exact mechanism of action is not specified in the provided information, but it is known to be a small molecule.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}